Clinical Trial Site Selection and Enrollment Optimization: Feasibility Data, Patient Findability, and Risk‑Based Startup

Published by Bles Software, a custom software and AI company based in Yehud-Monoson, Israel, building web apps, AI agents and API integrations for clients in Israel, the US, the UK and the EU.

Clinical development hinges on one brutal reality: trials fail to meet enrollment targets more often than they succeed. Missed recruiting curves translate into extended timelines, cost overruns, and delayed access to therapies for patients. Traditional site selection—asking investigators about “feasibility,” scanning old spreadsheets, and leaning on habit—struggles in a world where inclusion/exclusion criteria grow more precise, competing studies intensify, and patient access patterns shift with technology and social determinants of health. The result is predictable: sites that looked promising stall after a handful of screened patients, screen failure rates creep above plan, diversity targets remain unmet, and startup stretches from weeks to months.

This blueprint describes an end‑to‑end, data‑grounded approach to site selection and enrollment optimization. It covers feasibility inputs and how to make them empirical; scoring models that weight patient findability, operational velocity, competition, and site capacity; enrollment forecasting and dynamic reallocation; startup acceleration; and governance and ethics that keep the program auditable and respectful of participants. It also addresses the technology architecture and operating model required to make this work across sponsor, CRO, and site partners.

The Problem With Legacy Site Selection

Legacy approaches overweight self‑reported feasibility and underweight fresh, local patient realities. Investigators, often optimistic and motivated, estimate high but lack visibility into current competition or updated EHR coding patterns. Past performance is a strong signal but not sufficient: a site excellent in one oncology subtype may be weak in another due to referral paths and specialist coverage. Diversity and representation goals rarely influence selection beyond aspiration because data and modeling to operationalize them are absent.

Enrollment plans are frequently static. When a site stumbles, reallocation takes months, during which the overall curve slips. Startup artifacts—contracts, budgets, IRB submissions, regulatory documents—sit in email inboxes with variable cycle times. Meanwhile, patient findability deteriorates as competing studies launch and eligibility algorithms remain anchored in inclusion/exclusion text that humans interpret inconsistently.

Feasibility Inputs That Matter (and How to Obtain Them)

Feasibility must be grounded in measurable inputs:

  1. Historical trial performance: prior enrollment velocity for similar protocols, stratified by therapeutic area, indication, phase, and inclusion/exclusion complexity. Use public registries (ClinicalTrials.gov), sponsor history, and CRO data to compile site‑level metrics.
  2. Patient availability and findability: counts of potentially eligible patients within a catchment area derived from de‑identified EHR or claims data, adjusted for inclusion/exclusion approximations. Consider incidence and prevalence, practice patterns, and referral networks.
  3. Competition: overlapping or competing trials by geography and time window, with their enrollment velocity and sponsor reputation. High competition dampens achievable rates.
  4. Site capacity and operations: staff availability (coordinators, sub‑investigators), past task cycle times (contracting, budget, IRB), and activation velocity.
  5. Diversity potential: demographics of the catchment area relative to the trial’s representation goals; languages supported; community engagement infrastructure.

Obtaining these inputs requires data partnerships and careful privacy management. For EHR‑derived counts, use privacy‑preserving approaches: aggregations at the site or network level, or federated queries where algorithms run behind the firewall and return only counts. For claims, work with de‑identified datasets with sufficient geographic resolution. For competition, build a feed from public registries and specialized databases, cleaned and normalized.

Translating Inclusion/Exclusion Into Computable Criteria

Inclusion/exclusion (I/E) criteria are the crux of patient findability. They appear as long, nuanced text, with multiple alternatives, time windows (“within 6 months”), lab thresholds, and contraindications. Translating I/E into computable logic benefits from natural language processing and clinical coding expertise. A two‑step approach works well: use an LLM to segment and structure criteria (extract clinical concepts, operators, thresholds, and temporal qualifiers), then map those to standardized codes (ICD‑10, SNOMED CT, LOINC, RxNorm) with clinician review. Where granular clinical data is unavailable (e.g., lab values in claims), approximate eligibility with validated proxies and reflect the uncertainty in patient counts.

Maintain a library of criterion patterns with examples and coding hints. Standardize the representation of combined criteria (e.g., “A or B and C not D within 30 days”). Version the I/E translation and keep a change log across protocol amendments; the enrollment model should update accordingly.

Scoring Model for Site Selection

Construct a composite score that reflects the multi‑factor nature of site performance. Key components:

Each component should be scored on a 0–1 scale and combined with weights agreed by clinical operations and statistics. Present sub‑scores transparently so site teams can discuss tradeoffs. A site with stellar patient availability but chronic startup delays may still be selected if a parallel workstream accelerates activation.

Enrollment Forecasting and Dynamic Reallocation

Forecast enrollment as a curve per site and in aggregate. A practical model uses a ramp‑up period to steady‑state, with variability driven by site‑specific velocity, seasonality, and competition. Calibrate with historical curves and early readouts from the first few randomized patients. Avoid the trap of linear targets; human and operational systems pulse.

Establish a monthly reallocation ritual. If a site underperforms its forecast beyond a threshold and root causes are not rapidly correctable (e.g., eligibility mismatches, investigator departure), shift targets and resources to higher‑performing sites. Maintain a bench of pre‑qualified backup sites that can be activated quickly. Use the same scoring model to prioritize backups.

Model scenarios: “If Site A continues at 50% of plan and Site B accelerates by 30%, what is the impact on the overall timeline?” Provide visibility to program leadership and finance; reallocation decisions have budget implications (site budgets, monitoring travel, CRO hours).

Startup Acceleration and Risk‑Based Processes

Startup time kills promising enrollment. Map the critical path: CTA and budget negotiation, IRB approval, regulatory document collection, investigator training, and system setup (EDC, IRT). Instrument each task with timestamps and owners; many teams guess where time goes. Introduce parallelism where safe: contract templates pre‑negotiated with commonly used sites, budget guardrails, central IRB usage when acceptable, and eISF/eConsent systems that reduce paper churn.

Adopt risk‑based startup: classify sites into low/medium/high risk segments based on history and oversight needs. For low‑risk, streamline document checklists and enable self‑service uploads validated by automated checks (e.g., license validity against registries). For high‑risk, schedule early monitoring touchpoints and add contract clauses that tighten timelines with incentives or penalties. Keep the philosophy consistent with risk‑based monitoring later in the study; the same data that informs startup risk can guide early oversight intensity.

Patient Findability, Referral Paths, and Community Engagement

Patient counts from data are a starting point. Findability involves pathways: do potential participants visit the right clinics, and do those clinics have the coordination and equipment to screen and enroll? Map referral patterns: primary care to specialists, community hospital to academic centers. Identify and support community clinics that serve underrepresented populations; providing equipment or shared coordinators can transform their ability to participate.

Invest in multilingual outreach where demographics indicate need. Provide sites with IRB‑approved materials in relevant languages and channels (community radio, local associations). Equip sites with pre‑screening tools that implement the I/E logic consistently; even a simple, structured questionnaire on a tablet aligned to the computable criteria reduces screen failures substantially.

Diversity and Representation as First‑Class Targets

Representation targets should be operational, not aspirational. Translate program‑level diversity goals into site‑level targets informed by catchment demographics and historical performance. Monitor enrollment by demographic variables (race, ethnicity, age, sex) with privacy safeguards. If performance lags, adjust site mix and outreach. Provide sites with practical support: translated materials, travel stipends, flexible scheduling, and partnerships with community organizations.

Report diversity progress alongside total enrollment in governance meetings. Celebrate sites that excel and make diversity a criterion in ongoing selection—not a footnote.

Technology Architecture and Data Privacy

Implement a modular architecture that respects privacy. For EHR‑derived counts and feasibility queries, prefer federated or distributed computation: ship algorithms to sites or data networks, run behind the firewall, return only aggregate counts and, where approved, contact lists for pre‑screening under IRB. For claims, store de‑identified datasets with strict access controls and separation from operational systems. Keep an auditable boundary between de‑identified planning data and identified operational data used for actual patient contact.

Core components: (1) a protocol criteria service that stores structured I/E representations and generates computable logic for different data sources; (2) a feasibility query service that composes and dispatches queries to EHR networks or data partners; (3) a site scoring service with transparent weights and sub‑scores; (4) an enrollment forecasting and scenario module; (5) startup workflow with eISF integrations; and (6) dashboards for operations, medical, and leadership.

Security and compliance are non‑negotiable: HIPAA where applicable, 21 CFR Part 11 for electronic records, GDPR in relevant geographies, and robust role‑based access. Encrypt data in transit and at rest, log access, and routinely test controls. Treat model code (I/E translations, scoring logic) as validated software with versioning and change control.

Governance: Sponsor–CRO–Site Collaboration

Site selection and enrollment require tight collaboration. Define roles: sponsors set goals, provide protocol clarity, and own the scoring methodology; CROs execute startup, monitoring, and on‑the‑ground engagement; sites recruit and care for participants. Create a joint governance forum that reviews scores, forecasts, and blockers monthly. When a site falls behind, decide together whether to remediate (add resources, simplify workflows) or reallocate.

Offer sites transparency and value. Share how they score and why, and offer support plans to improve—training, coordinator time, or equipment. Where possible, provide sites with tools, not just asks: pre‑screening applications, patient engagement materials, and standardized workflows that lighten their burden.

Monitoring and Feedback Loops

Use early signals aggressively. Screen failure reasons, time from referral to screening, and screen‑to‑randomization conversion rates are leading indicators. If a criterion is causing many failures, revisit the I/E interpretation; sometimes a protocol amendment clarifies an ambiguity that sites interpreted differently. If a site has good pre‑screen numbers but slow conversions, investigate logistics: visit scheduling, lab turnaround, or consent complexity.

Create a continuous learning loop. Feed actual enrollment data back into the scoring model: did the site’s realized velocity match the forecast? Did startup friction metrics predict delays accurately? Update weights and criteria translations to reflect reality, not theory. Over time, the model should outperform any single stakeholder’s intuition—and be seen as fair because it is explainable and responsive.

Cost of Delay and Business Impact

Time is money in clinical development. Quantify the cost of delay explicitly: for each month of slippage, estimate additional CRO fees, site costs, and—most importantly—opportunity cost from delayed market entry. When leadership sees the financial curve, reallocation and investment in startup acceleration become easier decisions. Conversely, use the same framing to deprioritize activities that do not materially influence the timeline.

Ethical Considerations and Patient Respect

Optimization cannot trample ethics. Ensure that data use respects consent and privacy. Communicate clearly with potential participants; transparency about study goals, risks, and benefits builds trust. Avoid “over‑fishing” in communities where research fatigue is real; diversify sites to spread burden and benefit. Monitor for unfair burdens (excess travel, uncompensated time) and address them with stipends and flexible design when possible.

Inclusivity is not just a metric. It is the difference between a therapy that works in the abstract and one that helps the people who need it most. Treat representation as a scientific and moral requirement.

Implementation Roadmap: 120 Days to Better Curves

Day 0–30: finalize structured I/E, assemble historical performance data, acquire or activate EHR/claims feasibility pathways, and identify a pilot set of 30–50 candidate sites. Day 31–60: run feasibility queries, score sites, conduct structured interviews to validate assumptions, and select initial and backup cohorts. Day 61–90: instrument startup workflows, launch eISF/eConsent where possible, and set up dashboards and forecasting. Day 91–120: start enrollment, monitor leading indicators, and run the first reallocation cycle with scenario analysis.

Pick one therapeutic area with realistic data access for the pilot. Demonstrate a visible improvement in startup time and early enrollment vs a matched historical program. Use that to scale methodology and tooling across indications.

Case Examples

An immunology program struggled with screen failures due to a lab threshold criterion that sites interpreted inconsistently. Translating I/E into a computable logic surfaced that the threshold should be based on two consecutive measurements rather than one; an amendment and updated pre‑screen tool cut screen failures by 30%. In oncology, two high‑prestige academic centers underperformed due to competing trials and coordinator shortages; adding three community sites with strong referral networks restored the curve within a month.

In a cardiology device study, startup dragged due to local IRB cycles. A risk‑based approach that offered central IRB and standardized budgets reduced activation time by four weeks on average. Leadership adopted central IRB as default for similar risk profiles thereafter.

Common Pitfalls and Practical Fixes

Over‑indexing on prestige: flagship academic centers are vital but can be capacity‑constrained; balance with community sites that see more eligible patients day‑to‑day. Treat feasibility letters skeptically when unaccompanied by data. Avoid rigid curves; pulse resources where the data says momentum exists. Don’t let privacy concerns become an excuse for inaction—use federated counts and de‑identified planning until consented contact is permissible.

Most of all, write down decisions and outcomes. When a selection deviates from the score for a good reason (e.g., a site’s PI has unique expertise), record it. When a forecast misses, analyze why and adjust. Accumulated institutional learning is the secret weapon that turns models into durable advantage.

Investigator Networks and Collaboration Effects

Investigators operate within professional networks—referrals, shared fellows, and conference collaborations. Sites anchored by investigators embedded in active networks often recruit more reliably because they can tap colleagues for referrals and advice on operational challenges. Map co‑authorships, trial co‑participation, and society leadership roles to identify network hubs. When two borderline sites tie on scores, the one with stronger network centrality may deserve the nod. Offer structured collaboration opportunities: virtual investigator meetings for troubleshooting, shared best practices on pre‑screening scripts, and communal Q&A with medical monitors.

Beware over‑reliance on a single star PI; capacity and competing obligations can change quickly. Balance networks across geographies and institution types—academic centers, community hospitals, and private practices—so recruitment doesn’t stall if any one node slows.

Budgeting, Contracts, and Incentive Design

Contracts can either accelerate or choke startup. Standardize budget templates with pre‑agreed rates for common procedures and coordinator time. Where allowed, structure performance‑sensitive incentives carefully: milestone payments for activation speed and conversion rates can focus site attention without creating perverse incentives. Keep language clear on what counts as screen fail vs screen, and avoid ambiguities that lead to billing disputes.

From the sponsor side, resist penny‑wise delays. If adding a part‑time coordinator or reimbursing specific equipment accelerates enrollment by weeks, the cost is often dwarfed by the cost of delay. Analytics should make these tradeoffs explicit, showing the ROI of small operational investments.

Digital Recruitment, Ethics, and Practical Limits

Digital channels—search ads, social media, patient communities—are powerful but must be handled with care. Use them to increase awareness where sites have capacity and where inclusion criteria are straightforward to pre‑screen. Always route potential participants through IRB‑approved flow and provide materials that are accurate and empathetic. Avoid “spray and pray” campaigns that flood sites with unqualified leads; that burden burns goodwill. Instead, geotarget around selected sites, tune messaging to eligibility signals, and measure not clicks but qualified pre‑screens and randomizations.

Set expectations: digital outreach supplements, not replaces, strong site operations. A site with poor conversion will not be saved by more leads. Fix the funnel first.

Data Validation and Site Audits

Trust but verify. Where sites provide local feasibility numbers, ask for methodology and sample sizes. During enrollment, periodically audit counts against EDC and source documents to ensure metrics and forecasts remain grounded. Use audits as coaching, not punishment—point out data entry gaps that obscure visibility and offer solutions.

For algorithmic components (I/E translation, scoring weights), maintain validation documents. When auditors ask how a score was computed, produce the exact inputs, versions, and rationale. Treat this like any other validated system in regulated environments.

Operating Model and RACI Across Sponsor, CRO, and Sites

Clarify who owns what. Sponsors own protocol clarity, scoring methodology, diversity goals, and funding decisions. CROs own startup execution, site engagement, and monitoring. Sites own local recruitment, patient care, and data quality. Write this into a RACI and revisit quarterly. When something slips, the first question should not be “who is to blame?” but “who owns the lever to move this forward?”

Create escalation paths that move faster than monthly governance. If a site loses a coordinator unexpectedly, empower the CRO to reallocate temporary staff and inform the sponsor within 48 hours, rather than waiting for the next meeting. Small, fast interventions keep curves from derailing.

Protocol Design Feedback Loop

Many enrollment bottlenecks are baked into protocols—overly tight criteria, burdensome visit schedules, or procedures that require rare equipment. Establish a formal loop where early site feedback and screen failure analyses inform protocol amendments or clarifications. A medical monitor and statistician should evaluate whether relaxing a criterion (e.g., lab threshold timing) protects scientific integrity while broadening eligibility. Document each change’s rationale and expected enrollment impact; tie these to post‑amendment curves to learn what moves the needle.

Build pre‑protocol design heuristics from past programs: which criteria commonly cause high screen failure? Which visit burdens drive dropout? Pair these with patient advocacy perspectives to craft protocols participants can realistically complete. Designing for feasibility beats patching in the field.

Site Enablement Playbook

Equip sites with a standard kit: a computable pre‑screen questionnaire aligned to I/E, translated materials, a visit schedule visual that makes participant burden clear, and a checklist for activation tasks with target cycle times. Provide coordinator training modules and quick‑reference guides. Where possible, offer shared resources: floating coordinators, telehealth options for certain visits, and courier services for labs.

Measure enablement effects. Sites that adopt the kit should show higher screen‑to‑randomize conversion and faster startup. If not, refine the kit rather than blame adoption; perhaps the pre‑screen misses a common disqualifier, or the materials aren’t in the right languages.

Metrics and Dashboards That Matter

Design dashboards for action. For operations: startup cycle time by task and site, enrollment vs forecast curves, screen failure reasons, and site capacity signals (coordinator load). For medical: inclusion/exclusion ambiguity heatmap and protocol question volume. For leadership: overall curve vs plan, reallocation decisions and their impact, diversity progress, and cost‑of‑delay projections.

Keep context next to numbers. If a curve shifts due to a protocol amendment or a site’s equipment issue, annotate the chart. Provide drill‑downs that go from program to site to participant journey (with privacy) so teams don’t debate averages when the issue is local.

Finally, make dashboards two‑way. Allow site coordinators to flag data quality issues or contextual notes directly on the metrics they own, with workflow to resolve and mark as addressed. When the people closest to execution can annotate what the numbers mean—“holiday staffing reduced screening by 40% this week” or “new lab machine installed; throughput will improve next week”—leadership decisions become smarter and less reactive. Treat the system as a shared communication surface, not a one‑way report.

Regulatory Alignment and Audit Readiness

Regulators expect traceability from design to decision. For every model‑assisted step—criteria translation, site scoring, reallocation—maintain documentation: inputs, assumptions, version identifiers, and human approvals. Keep SOPs that define when algorithmic suggestions require medical or operational sign‑off. Validate electronic systems used for startup (eISF, eConsent) against Part 11 or equivalent and train site staff accordingly. During inspections, demonstrate that participant protection and data integrity were the north stars; optimization served those ends.

Avoid opaque black boxes. If a site questions why they were not selected, be able to show the sub‑scores and data that led to the outcome. When human judgment overrode the score, document the rationale. Transparency builds trust among partners and eases regulatory conversations.

Closing the Loop Post‑Study

After database lock, harvest lessons methodically. Compare planned vs actual enrollment by site, screen failure reasons, and time‑to‑activation. Which heuristics predicted well and which didn’t? Archive criteria translations, scoring weights, and forecasts with outcomes so future teams avoid rediscovering the same lessons. Recognize sites that excelled; sustained partnerships with high‑performing, well‑supported sites are a durable competitive advantage.

Finally, share learnings with participants and communities where appropriate. Respect privacy, but acknowledge contributions. When communities feel valued, future recruitment becomes easier and more ethical.

Funding and Portfolio Prioritization

Enrollment speed is a portfolio lever. Tie program funding gates to evidence that site selection and startup are data‑driven. Programs that demonstrate computable criteria, empirical feasibility, and clear reallocation plans should advance faster through internal governance. Conversely, require remediation plans for programs that persist with purely anecdotal feasibility. Finance partners appreciate forecasts grounded in data; in return, they can unlock contingency funds for rapid activation of backup sites when scenarios show clear ROI.

At the portfolio level, model cross‑program resource contention—CRO monitoring bandwidth, internal medical monitor time, and shared site capacity. Sometimes a small shift in start dates or reallocation of central resources improves enrollment across multiple programs. Make these tradeoffs explicit in quarterly portfolio reviews so leadership optimizes for aggregate time‑to‑value, not just individual program optics.

A disciplined, portfolio‑aware approach turns enrollment from a crisis response into an engineered, predictable capability across studies.

FAQ

How do we translate nuanced inclusion/exclusion criteria into something data teams can query?

Use a two‑step approach: first, have clinicians and NLP segment the criteria into structured components with concepts, operators, and time windows; second, map those to standardized codes and computable logic. Maintain a library of patterns and versions per amendment. For sites without deep data access, run simplified proxy queries with known limitations and communicate the uncertainty in counts.

What if we don’t have access to EHR networks that support federated queries?

Start with claims data for incidence/prevalence and referral patterns and combine with public registry competitive intelligence. Add structured pre‑screen tools to sites to quickly gather real‑world local counts. Meanwhile, pursue partnerships with health systems and data networks; feasibility without any local data is guesswork.

How do we incorporate diversity goals without compromising enrollment speed?

Treat representation as a hard requirement in site mix and outreach plans, not as a nice‑to‑have. Select sites in communities aligned to target demographics and support them with materials and logistics. Monitor enrollment by demographic variables in near‑real time; if you lag, reallocate early. In practice, programs that plan for diversity from day one enroll faster because outreach and logistics are thought through.

How often should we refresh site scores and forecasts?

Monthly at minimum during startup and early enrollment, with an ability to run ad‑hoc when competition shifts or a site undergoes staffing changes. Early in a study, small updates matter; later, stability increases and refresh can be quarterly.

What metrics matter most for leadership?

Show startup cycle times by task, enrollment vs forecast curves, screen failure reasons, reallocation decisions and outcomes, and diversity progress. Tie all to the “cost of delay” model so decisions are financially grounded. Avoid vanity metrics; enrollments and time saved are the headline.

How do we protect privacy while doing meaningful feasibility?

Use federated or de‑identified data wherever possible until consent is obtained. Ensure role‑based access, encrypt data, and log usage. Keep a clean separation between planning datasets and operational patient data. Work with legal and IRB early to design acceptable processes rather than trying to retrofit privacy at the end.

Where do CROs fit if sponsors build these capabilities?

CROs remain essential execution partners. Sponsors can own scoring methodology and governance while CROs operate startup, monitoring, and site engagement with these tools. Shared dashboards and clear RACI prevent turf battles and speed decisions.

More Use Cases from Bles Software